Anti-tumor-associated gangliosides [PolrecCHOIgM/GD3], Human IgG1, Fc Silent(tm), kappa

Absolute Antibody

Anti-tumor-associated gangliosides [PolrecCHOIgM/GD3], Human IgG1, Fc Silent(tm), kappa

9

The original antibody (recombinant human IgM) was designed to bind the ganglioside GD3, which is overexpressed in malignant cells like melanomas. ELISA testing revealed strong binding specificity to GD3, GM1, GD2, and GM3 gangliosides, even at low concentrations. In cell-line assays, it selectively bound cancer cell lines (melanoma, lung, breast, and glioblastoma), without binding to normal cells such as huVEC and lung fibroblasts. Immunoimaging confirmed this selective binding, with fluorescence indicating strong interaction with malignant cells. In vitro complement activation tests showed that the antibody triggered cancer cell lysis when exposed to normal human serum, demonstrating its ability to activate the complement cascade. The antibody thus effectively discriminates between malignant and normal cells, confirming its diagnostic and therapeutic utility in cancer (US10590204B2).

Functional Assay, ImmunoFluorescence, ELISA, Other Application

Research Use Only

Monoclonal

PolrecCHOIgM/GD3

Human

IgG1

This reformatted human antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques.

Human

-20°C,2°C to 8°C

41116161